Causaly: Beyond Search, Into Scientific Decisions

Overview: How Causaly’s AI-Driven Scientific Evidence Search & Research Intelligence Platform Transforms Biopharma R&D

Causaly is an AI-powered scientific evidence search and research intelligence platform that connects biomedical information to support evidence assessment, hypothesis exploration and research decisions. It addresses a persistent bottleneck in life sciences: relevant findings are dispersed across publications, clinical trials, patents and internal knowledge, making it difficult to assemble a coherent view of a biological question. Beyond retrieving documents, the platform helps organise supporting findings, contradictory evidence and unanswered questions into structured assessments.

Causaly combines semantic search, knowledge graphs and coordinated AI agents to retrieve evidence, connect biological relationships and apply repeatable scientific workflows. Its approach links scientific information with biological mechanisms and development activity, supporting tasks such as target assessment, indication prioritisation and clinical evidence comparison. Source passages and the reasoning behind outputs remain available for inspection, allowing findings to be reviewed in context rather than treated as definitive answers.

Operationally, Causaly can reduce manual searching and evidence collation while making assessments more consistent and reviewable. Research findings can be organised into target dossiers, evidence briefs and reports that retain the rationale and open questions behind a scientific position. The practical value is a shorter path from fragmented information to an assessment ready for review, alongside clearer visibility into evidence gaps; expert interpretation remains essential before findings inform research priorities.

Last checked on October 24, 2026: Causaly’s latest listed announcement adds access to its scientific research capabilities within Microsoft 365 Copilot, following the September 17, 2026 availability announcement.

What is Causaly?

Causaly is a scientific evidence search and research intelligence platform that connects biomedical literature, clinical trials, patents and internal knowledge to support target assessment, indication prioritisation, clinical evidence review and medical affairs. It serves scientific teams in pharmaceutical, biotechnology and other life sciences organisations. Its technical approach combines AI agents, biomedical knowledge graphs, and semantic and graph-based retrieval to produce structured assessments with inspectable source passages, evidence gaps and reasoning for expert review.

Intended Use and Limitations

• Causaly announced ISO 27001 certification in June 2022; the announcement does not establish the certificate’s current validity, scope or expiry date.

• A strategic partnership with Syneos Health, announced in August 2026, covers deployment across scientific functions including medical advisory, real-world evidence and clinical-development research.

• Causaly’s Microsoft collaboration connects scientific computation with evidence-grounded research workflows, providing an enterprise technology partnership relevant to integration planning.

• Its Sage partnership enables access to full-text journal articles through mutual customers’ existing institutional licences, supporting licensed access to underlying scientific evidence.

• Reported customers include Gilead, Novo Nordisk and Regeneron; these relationships indicate pharmaceutical adoption but do not independently validate every product capability.

• FDA and National Institute of Environmental Health Sciences use was reported in 2023; use by a regulator does not constitute regulatory approval or endorsement.

• Causaly raised a $60 million Series B led by ICONIQ Growth in July 2023, bringing reported total funding to $93 million; historical funding does not establish current financial runway.